Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.65 |
| ▸ | MAOA | P21397 | 5/20 | 0.61 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | RXRB | P28702 | 1/20 | 0.58 |
| ▸ | RXRG | P48443 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31703424 | 0.98 | MAOB (0.66) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL22874580 | 0.84 | MAOB (0.60) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL22967634 | 0.84 | MAOB (0.60) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL22967378 | 0.83 | MAOB (0.60) | MAOBMAOAAPP | |
| SCHEMBL10169470 | 0.82 | MAOB (0.71) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL10600292 | 0.81 | MAOB (0.69) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL4343925 | 0.81 | MAOB (0.65) | MAOBMAOAAPP | |
| SCHEMBL21340758 | 0.81 | MAOB (0.68) | MAOBAPP | |
| SCHEMBL4417319 | 0.81 | MAOB (0.73) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL3624161 | 0.80 | MAOB (0.73) | MAOBMAOARXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-10 | — | — | US | disclosed |
| EP-3760633-B1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | ACCSALUS BIOSCIENCES LIMITED (VG) | 2021-02-11 | — | — | US | disclosed |
| EP-3760633-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | WNK1, WNK2, WNK3 | MAOB 975/4885MAOA 1220/4885RXRA 3567/4885 |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | WNK1, WNK2, WNK3 | MAOB 975/4885MAOA 1220/4885RXRA 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.